

SETTLEMENT AGREEMENT

This Settlement Agreement (“Agreement”) is entered into among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General of the Department of Health and Human Services (“OIG-HHS”) (collectively the “United States”), AstraZeneca LP and AstraZeneca Pharmaceuticals LP (collectively “AstraZeneca”), and Ronald J. Streck (“Relator”) (hereafter collectively referred to as “the Parties”), through their authorized representatives.

RECITALS

A. AstraZeneca LP and AstraZeneca Pharmaceuticals LP are Delaware limited partnerships with their principal places of business in Wilmington, Delaware. At all relevant times, AstraZeneca distributed and sold pharmaceutical products in the United States.

B. On October 28, 2008, Relator filed a *qui tam* action in the United States District Court for the Eastern District of Pennsylvania captioned *United States, State of California, State of Connecticut, State of Delaware, State of Florida, State of Georgia, State of Hawaii, State of Illinois, State of Indiana, State of Louisiana, The Commonwealth of Massachusetts, State of Michigan, State of Montana, State of Nevada, State of New Hampshire, State of New Jersey, State of New Mexico, State of New York, State of North Carolina, State of Oklahoma, State of Rhode Island, State of Tennessee, State of Texas, The Commonwealth of Virginia, State of Wisconsin, The District of Columbia, ex rel. Ronald J. Streck v. Allergan et al.*, 08-CV-5135, pursuant to the *qui tam* provisions of the False Claims Act, 31 U.S.C. § 3730(b) and the false claims statutes of

the plaintiff states (the “Civil Action”). Relator filed amended complaints on or about January 12, 2009, May 20, 2010, April 25, 2011, and September 29, 2011. AstraZeneca was named as a defendant in Relator’s original and amended complaints.

C. At all relevant times, AstraZeneca participated in the Medicaid Drug Rebate Program, 42 U.S.C. § 1396r-8, which is part of the federal Medicaid Program, Title XIX of the Social Security Act, 42 U.S.C. §§ 1396-1396w-5.

D. The United States contends that AstraZeneca made or caused to be made statements material to the payment of rebates pursuant to the Medicaid Drug Rebate Program and statements material to payments made by the United States to the states for the Medicaid Program.

E. The United States contends that it has certain civil claims against AstraZeneca for engaging in the following conduct during the period from October 1, 2007 through June 30, 2014 (hereafter referred to as the “Covered Conduct”):

1. Pursuant to the Medicaid Drug Rebate Program, AstraZeneca was required to report the Average Manufacturer Price (“AMP”) for each of its covered outpatient drugs to the Centers for Medicare and Medicaid Services (“CMS”) on a monthly and quarterly basis, and to pay quarterly rebates to state Medicaid programs that were based, in part, on the quarterly AMPs reported by AstraZeneca. Prior to enactment of the Affordable Care Act (“ACA”), the AMP for a drug generally was based on the average unit price paid to the manufacturer for the drug by wholesalers for drugs distributed to the retail pharmacy class of trade, including cash discounts and other price concessions that reduced the actual price paid for the drug. The ACA revised the definition of AMP, in part, by replacing the term “retail pharmacy class of trade” with

“retail community pharmacies” and including manufacturer direct sales to pharmacies. Both before and after enactment of the ACA, bona fide service fees are excluded from manufacturers’ AMP calculations.

2. AstraZeneca entered into distribution services agreements with wholesalers (“Distribution Services Agreements”) to facilitate the distribution and sale of the pharmaceuticals listed on Attachment A hereto (“the Covered Drugs”). Pursuant to the Distribution Services Agreements, the wholesalers performed various specified services, and AstraZeneca compensated the wholesalers for performing those services by providing the wholesalers quarterly credits calculated as a percentage of the quarterly sales of the Covered Drugs, subject to certain performance penalties based on criteria set forth in the agreements.

3. The United States contends that AstraZeneca improperly treated compensation provided to the wholesalers pursuant to the Distribution Services Agreements as price reductions, rather than as bona fide service fees, in calculating and reporting quarterly AMPs to CMS for the Covered Drugs. As a result of AstraZeneca’s reporting such improperly reduced AMPs, the United States contends that AstraZeneca underpaid quarterly rebates owed to the states for the Covered Drugs under the Medicaid Drug Rebate Program, and caused the United States to be overcharged for its payments to the states for the Medicaid Program.

F. AstraZeneca denies the United States’ allegations in Paragraph E and Relator’s allegations in the Civil Action.

G. AstraZeneca will be entering into separate settlement agreements, described in paragraph 1.b below (hereinafter referred to as the “Medicaid State

Settlement Agreements”) with certain states and the District of Columbia in settlement of the Covered Conduct. States with which AstraZeneca executes a Medicaid State Settlement Agreement in the form to which AstraZeneca and the National Association of Medicaid Fraud Control Units (“NAMFCU”) have agreed, or in a form otherwise agreed to by AstraZeneca and an individual state, are referred to herein as “Medicaid Participating States.”

H. This Settlement Agreement is neither an admission of liability by AstraZeneca nor a concession by the United States that its claims are not well founded.

I. Relator claims entitlement under 31 U.S.C. § 3730(d) to a share of the proceeds of this Settlement Agreement and to Relator’s reasonable expenses, attorneys’ fees and costs.

To avoid the delay, uncertainty, inconvenience, and expense of protracted litigation of the above claims, and in consideration of the mutual promises and obligations of this Settlement Agreement, the Parties agree and covenant as follows:

TERMS AND CONDITIONS

1. AstraZeneca shall pay to the United States and the Medicaid Participating States, collectively, the sum of \$46,500,000.00 (“Settlement Amount”) and interest on the Settlement Amount at a rate of 1.625% per annum from February 20, 2015. The Settlement Amount shall constitute a debt immediately due and owing to the United States and the Medicaid Participating States. The debt shall be discharged by payments to the United States and Medicaid Participating States as follows:

a. AstraZeneca shall pay to the United States the sum of \$26,670,744.67 plus interest thereon at a rate of 1.625% per annum from February 20, 2015 to and including the Effective Date of this Agreement (the “Federal Settlement Amount”). AstraZeneca shall pay the Federal Settlement Amount to the United States by electronic funds transfer pursuant to written instructions to be provided by the United States by the Effective Date of this Agreement. AstraZeneca shall make this electronic funds transfer no later than five business days after the Effective Date of this Agreement.

b. AstraZeneca shall pay to the Medicaid Participating States the sum of \$19,829,255.33 plus interest thereon at a rate of 1.625% per annum from February 20, 2015 (the “State Settlement Amount”). The State Settlement Amount shall be paid by electronic funds transfer in accordance with written instructions to be provided by the NAMFCU negotiating team pursuant to the terms and conditions agreed upon by AstraZeneca and the NAMFCU negotiating team and as set forth in the Medicaid State Settlement Agreements that AstraZeneca will enter into with the Medicaid Participating States.

2. Subject to the exceptions in Paragraph 5 (concerning excluded claims) below, and conditioned upon AstraZeneca’s full payment of the Settlement Amount, the United States releases AstraZeneca, together with its current and former parents, subsidiaries, divisions, successors, transferees, heirs and assigns, and their current and former directors, officers, and employees (the “AstraZeneca Released Parties”), from any civil or administrative monetary claim the United States has for the Covered Conduct under the False Claims Act, 31 U.S.C. §§ 3729-3733; the Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a; the Program Fraud Civil Remedies Act, 31 U.S.C. §§ 3801-3812;

the Medicaid Rebate Statute, 42 U.S.C. § 1396r-8 (including any such claim for the Covered Conduct under the rebate agreement AstraZeneca executed pursuant to the statute or based on an administrative restatement of AMP pursuant to the statute); or the common law theories of payment by mistake, unjust enrichment, and fraud.

3. Subject to the exceptions in Paragraph 5 below, and conditioned upon AstraZeneca's full payment of the Settlement Amount, Relator for himself and for his heirs, successors, attorneys, agents, and assigns, releases the AstraZeneca Released Parties from any civil monetary claim Relator has on behalf of the United States for the Covered Conduct under the False Claims Act, 31 U.S.C. §§ 3729-3733 and from all liability, claims, demands, actions, or causes of action whatsoever, whether known or unknown, fixed or contingent, in law or in equity, in contract or in tort, under any federal or state statute or regulation, or in common law, that Relator, his heirs, successors, attorneys, agents and assigns otherwise would have standing to bring as of the date of this Agreement, including any liability to Relator arising from or relating to the claims Relator asserted or could have asserted in the Civil Action. Relator's release of the AstraZeneca Released Parties does not extend to Relator's statutory claim for reasonable attorneys' fees, expenses and costs resulting from the Civil Action pursuant to 31 U.S.C. § 3730(d) ("Relator's Statutory Claim").

4. In consideration of the obligations of AstraZeneca in this Agreement and a certification from AstraZeneca relating to government pricing practices in the United States, and conditioned upon AstraZeneca's full payment of the Settlement Amount, the OIG-HHS agrees to release and refrain from instituting, directing, or maintaining any administrative action seeking exclusion from Medicare, Medicaid, and other Federal

health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) against AstraZeneca under 42 U.S.C. § 1320a-7a (Civil Monetary Penalties Law) or 42 U.S.C. § 1320a-7(b)(7) (permissive exclusion for fraud, kickbacks, and other prohibited activities) for the Covered Conduct, except as reserved in Paragraph 5 (concerning excluded claims), below, and as reserved in this Paragraph. The OIG-HHS expressly reserves all rights to comply with any statutory obligations to exclude AstraZeneca from Medicare, Medicaid, and other Federal health care programs under 42 U.S.C. § 1320a-7(a) (mandatory exclusion) based upon the Covered Conduct. Nothing in this Paragraph precludes the OIG-HHS from taking action against entities or persons, or for conduct and practices, for which claims have been reserved in Paragraph 5, below.

5. Notwithstanding the releases given in paragraphs 2 and 3 of this Agreement, or any other term of this Agreement, the following claims of the United States are specifically reserved and are not released:

- a. Any liability arising under Title 26, U.S. Code (Internal Revenue Code);
- b. Any criminal liability;
- c. Except as explicitly stated in this Agreement, any administrative liability, including mandatory exclusion from Federal health care programs;
- d. Any liability to the United States (or its agencies) for any conduct other than the Covered Conduct;
- e. Any liability based upon obligations created by this Agreement;

- f. Any liability for express or implied warranty claims or other claims for defective or deficient products or services, including quality of goods and services;
- g. Any liability for failure to deliver goods or services due; or
- h. Any liability for personal injury or property damage or for other consequential damages arising from the Covered Conduct.

6. Relator and his heirs, successors, attorneys, agents, and assigns shall not object to this Agreement but agree and confirm that this Agreement is fair, adequate, and reasonable under all the circumstances, pursuant to 31 U.S.C. § 3730(c)(2)(B). In connection with this Agreement and this Civil Action, Relator and his heirs, successors, attorneys, agents, and assigns agree that neither this Agreement, any motion to intervene or intervention by the United States in the Civil Action in order to dismiss any portion of the Civil Action, nor any dismissal of any portion of the Civil Action, shall waive or otherwise affect the ability of the United States to contend that provisions in the False Claims Act, including 31 U.S.C. §§ 3730(d)(3) and 3730(e), bar Relator from sharing in the proceeds of this Agreement. The United States agrees that neither this Agreement, nor any dismissal of claims asserted against AstraZeneca in the Civil Action pursuant to this Agreement, shall waive or otherwise affect the ability of Relator to oppose intervention by the United States in the Civil Action, or to contend, should intervention occur, that Relator is entitled to a share of between 15% and 30% of the Federal Settlement Amount. Moreover, the United States and Relator and his heirs, successors, attorneys, agents, and assigns agree that they each retain all of their rights pursuant to the False Claims Act on the issue of the share percentage, if any, that Relator should receive

of any proceeds of this Settlement Agreement, and that no agreements concerning Relator's share have been reached to date.

7. AstraZeneca waives and shall not assert any defenses AstraZeneca may have to any criminal prosecution or administrative action relating to the Covered Conduct that may be based in whole or in part on a contention that, under the Double Jeopardy Clause in the Fifth Amendment of the Constitution, or under the Excessive Fines Clause in the Eighth Amendment of the Constitution, this Agreement bars a remedy sought in such criminal prosecution or administrative action. Nothing in this paragraph or any other provision of this Agreement constitutes an agreement by the United States concerning the characterization of the Settlement Amount for purposes of the Internal Revenue laws, Title 26 of the United States Code.

8. AstraZeneca fully and finally releases the United States, its agencies, officers, agents, employees, and servants, from any claims (including attorney's fees, costs, and expenses of every kind and however denominated) that AstraZeneca has asserted, could have asserted, or may assert in the future against the United States, its agencies, officers, agents, employees, and servants, related to the Covered Conduct and the United States' investigation and prosecution thereof.

9. AstraZeneca fully and finally releases Relator and his heirs, successors, attorneys, agents, and assigns, from any claims (including attorney's fees, costs, and expenses of every kind and however denominated) that AstraZeneca has asserted, could have asserted, or may assert in the future against Relator and his heirs, successors, attorneys, agents, and assigns, related to the filing of the Civil Action and Relator's investigation and prosecution thereof.

10. The Settlement Amount shall not be decreased as a result of the denial of claims for payment now being withheld from payment by any federal or state payer related to the Covered Conduct; and AstraZeneca agrees not to resubmit to any federal or state payer any previously denied claims related to the Covered Conduct, and agrees not to appeal any such denials of claims.

11. AstraZeneca agrees to the following:

a. Unallowable Costs Defined: All costs (as defined in the Federal Acquisition Regulation, 48 C.F.R. § 31.205-47; and in Titles XVIII and XIX of the Social Security Act, 42 U.S.C. §§ 1395-1395kkk and 1396-1396w-5; and the regulations and official program directives promulgated thereunder) incurred by or on behalf of AstraZeneca, its present or former officers, directors, employees, shareholders, and agents in connection with:

- (1) the matters covered by this Agreement;
- (2) the United States' audit(s) and civil investigation(s) of the matters covered by this Agreement;
- (3) AstraZeneca's investigation, defense, and corrective actions undertaken in response to the United States' audit(s) and civil investigation(s) in connection with the matters covered by this Agreement (including attorney's fees);
- (4) the negotiation and performance of this Agreement; and

- (5) the payment AstraZeneca makes to the United States or any State pursuant to this Agreement or the Medicaid State Settlement Agreements, and any payments that AstraZeneca may make to Relator, including costs and attorney's fees;

are unallowable costs for government contracting purposes and under the Medicare Program, Medicaid Program, TRICARE Program, and Federal Employees Health Benefits Program (FEHBP) (hereinafter referred to as "Unallowable Costs").

b. Future Treatment of Unallowable Costs: Unallowable Costs shall be separately determined and accounted for by AstraZeneca, and AstraZeneca shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by AstraZeneca or any of its subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.

c. Treatment of Unallowable Costs Previously Submitted for Payment: AstraZeneca further agrees that within 90 days of the Effective Date of this Agreement it shall identify to applicable Medicare and TRICARE fiscal intermediaries, carriers, and/or contractors, and Medicaid and FEHBP fiscal agents, any Unallowable Costs (as defined in this Paragraph) included in payments previously sought from the United States, or any State Medicaid program, including, but not limited to, payments sought in any cost reports, cost statements, information reports, or payment requests already submitted by AstraZeneca or any of its subsidiaries or affiliates, and shall

request, and agree, that such cost reports, cost statements, information reports, or payment requests, even if already settled, be adjusted to account for the effect of the inclusion of the Unallowable Costs. AstraZeneca agrees that the United States, at a minimum, shall be entitled to recoup from AstraZeneca any overpayment plus applicable interest and penalties as a result of the inclusion of such Unallowable Costs on previously-submitted cost reports, information reports, cost statements, or requests for payment.

Any payments due after the adjustments have been made shall be paid to the United States pursuant to the direction of the Department of Justice and/or the affected agencies. The United States reserves its rights to disagree with any calculations submitted by AstraZeneca or any of its subsidiaries or affiliates on the effect of inclusion of Unallowable Costs (as defined in this Paragraph) on AstraZeneca or any of its subsidiaries or affiliates' cost reports, cost statements, or information reports.

d. Nothing in this Agreement shall constitute a waiver of the rights of the United States to audit, examine, or re-examine AstraZeneca's books and records to determine that no Unallowable Costs have been claimed in accordance with the provisions of this Paragraph.

12. This Agreement is intended to be for the benefit of the Parties only. The Parties do not release any claims against any other person or entity, except to the extent provided for in Paragraph 13 (waiver for beneficiaries paragraph), below.

13. AstraZeneca agrees that it waives and shall not seek payment for any of the health care billings covered by this Agreement from any health care beneficiaries or

their parents, sponsors, legally responsible individuals, or third party payors based upon the claims defined as Covered Conduct.

14. Upon receipt of the payment described in Paragraph 1.a, above, the United States shall promptly file in the Civil Action a motion to intervene in the Civil Action to effectuate this Settlement Agreement, request dismissal with prejudice of all claims asserted against AstraZeneca on behalf of the United States in the Civil Action for the Covered Conduct released in this Settlement Agreement, request dismissal of all claims asserted against AstraZeneca on behalf of the United States in the Civil Action for other than the Covered Conduct with prejudice to Relator but without prejudice to the United States or the States, and request that the Court retain jurisdiction over any unresolved matters concerning Relator's claim for a share of the proceeds of this Settlement Agreement, and Relator's claim to recover expenses, attorneys' fees and costs from AstraZeneca, pursuant to 31 U.S.C. § 3730(d). Relator reserves all rights to oppose intervention by the United States in the Civil Action, but Relator agrees to join the United States's request for dismissal of all claims asserted against AstraZeneca on behalf of the United States in the Civil Action, provided the Court agrees to retain jurisdiction over any unresolved matters concerning Relator's claim for a share of the proceeds of this Settlement Agreement, and Relator's claim to recover expenses, attorneys' fees and costs from AstraZeneca, pursuant to 31 U.S.C. § 3730(d).

15. Each Party shall bear its own legal and other costs incurred in connection with this matter, including the preparation and performance of this Agreement, except for Relator's Statutory Claim as reserved in paragraph 3, above.

16. Each party and signatory to this Agreement represents that it freely and voluntarily enters in to this Agreement without any degree of duress or compulsion.

17. This Agreement is governed by the laws of the United States. The exclusive jurisdiction and venue for any dispute relating to this Agreement is the United States District Court for the Eastern District of Pennsylvania. For purposes of construing this Agreement, this Agreement shall be deemed to have been drafted by all Parties to this Agreement and shall not, therefore, be construed against any Party for that reason in any subsequent dispute.

18. This Agreement constitutes the complete agreement between the Parties. This Agreement may not be amended except by written consent of the Parties.

19. The undersigned counsel represent and warrant that they are fully authorized to execute this Agreement on behalf of the persons and entities indicated below.

20. This Agreement may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same Agreement.

21. This Agreement is binding on AstraZeneca's successors, transferees, heirs, and assigns.

22. This Agreement is binding on Relator's successors, transferees, heirs, and assigns.

23. All Parties consent to the United States' disclosure of this Agreement, and information about this Agreement, to the public.

24. This Agreement is effective on the date of signature of the last signatory to the Agreement ("Effective Date of this Agreement"). Facsimiles of signatures and/or


electronic signatures in portable document format (.pdf) shall constitute acceptable, binding signatures for purposes of this Agreement.

[Remainder of page intentionally left blank; signature pages to follow.]

THE UNITED STATES OF AMERICA


DATED: 7/6/15

BY:


JUSTIN DRAYCOTT
JEFFREY A. TOLL

Trial Attorneys
Commercial Litigation Branch
Civil Division
United States Department of Justice

DATED: 6/12/15


JANE DAVID MEMEGER


United States Attorney
Eastern District of Pennsylvania

DATED: 6/12/15


MARGARET L. HUTCHINSON

Chief, Civil Division
Assistant United States Attorney
Eastern District of Pennsylvania

DATED: 6/12/15


ERIC D. GILL

Assistant United States Attorney
Eastern District of Pennsylvania

DATED: _____

BY:

ROBERT K. DECONTI
Assistant Inspector General for Legal Affairs
Office of Counsel to the Inspector General
Office of Inspector General
United States Department of
Health and Human Services

THE UNITED STATES OF AMERICA

DATED: _____

BY: _____

JUSTIN DRAYCOTT
JEFFREY A. TOLL
Trial Attorneys
Commercial Litigation Branch
Civil Division
United States Department of Justice

DATED: _____

ZANE DAVID MEMEGER
United States Attorney
Eastern District of Pennsylvania

DATED: _____

MARGARET L. HUTCHINSON
Chief, Civil Division
Assistant United States Attorney
Eastern District of Pennsylvania

DATED: _____

ERIC D. GILL
Assistant United States Attorney
Eastern District of Pennsylvania

DATED: 7/6/15

BY: _____

Robert K. DeConti
ROBERT K. DECONTI
Assistant Inspector General for Legal Affairs
Office of Counsel to the Inspector General
Office of Inspector General
United States Department of
Health and Human Services

ASTRAZENECA LP and ASTRAZENECA PHARMACEUTICALS LP

DATED: 30 JUNE 2015

BY:


PAUL HUDSON
President, US and Executive Vice
President, North America
AstraZeneca LP and AstraZeneca
Pharmaceuticals LP

DATED: _____

BY:

ANDREW D. SCHAU
MATTHEW J. O'CONNOR
Covington & Burling LLP

and

DATED: _____

BY:

MICHAEL P. KELLY
McCarter & English LLP

Counsel for AstraZeneca LP and AstraZeneca
Pharmaceuticals LP

ASTRAZENECA LP and ASTRAZENECA PHARMACEUTICALS LP

DATED: _____

BY: _____

PAUL HUDSON
President, US and Executive Vice
President, North America
AstraZeneca LP and AstraZeneca
Pharmaceuticals LP

DATED: 6/30/2015

BY: _____


ANDREW D. SCHAU
MATTHEW J. O'CONNOR
Covington & Burling LLP

and

DATED: 6/30/2015


BY: _____


MICHAEL P. KELLY
McCarter & English LLP

Counsel for AstraZeneca LP and AstraZeneca
Pharmaceuticals LP

RONALD J. STRECK - RELATOR

DATED: 6/12/2015


BY: 
RONALD J. STRECK
Relator

DATED: 6/12/15

BY: 
DANIEL R. MILLER
TODD S. COLLINS
Berger & Montague

and

DATED: 6/12/15

BY: 
TALYANA BROMBERG
Faruqi & Faruqi

Counsel for Ronald J. Streck

ATTACHMENT A COVERED DRUGS

NDC	DRUG NAME
00186000131	Lexxel 5-5mg 30x1TAB Bottle
00186000168	Lexxel 5-5mg 100x1TAB Bottle
00186000231	Lexxel 5-2.5 mg 30x1TAB Bottle
00186000431	Atacand 4mg
00186000831	Atacand 8mg
00186001628	Atacand 16m
00186001631	Atacand 16m
00186001654	Atacand 16m
00186003228	Atacand 32m
00186003231	Atacand 32m
00186003254	Atacand 32m
00186016228	Atacand HCT
00186016254	Atacand HCT
00186021203	Xylocaine Inj 1.5% Spinal w/Dextrose 10x2ML Package
00186026092	Xylocaine Inj 1.0% Epi:200 5x30ML Ampule Dispenser
00186032228	Atacand HCT
00186032254	Atacand HCT
00186032454	Atacand HCT
00186036011	Xylocaine Viscous 2% 1x450ML Package
00186037020	Symbicort 1
00186037028	Symbicort 1
00186037220	Symbicort 8
00186037228	Symbicort 8
00186042504	Budesonide
00186042604	Budesonide
00186045028	Plendil 2.5mg 100x1TAB Hospital Unit Dose
00186045058	Plendil 2.5mg 100x1TAB Bottle
00186045128	Plendil 5mg 100x1TAB Hospital Unit Dose
00186045158	Plendil 5mg 100x1TAB Bottle
00186045228	Plendil 10mg 100x1TAB Hospital Unit Dose
00186045258	Plendil 10mg 100x1TAB Bottle
00186051060	Vimovo 375
00186052039	Vimovo 500
00186052060	Vimovo 500
00186060631	Prilosec 10
00186060682	Prilosec 10
00186061001	Prilosec Fo
00186062501	Prilosec Fo

00186070210	Entocort EC
00186074231	Prilosec 20
00186074282	Prilosec 20
00186074331	Prilosec 40
00186074368	Prilosec 40
00186074382	Prilosec 40
00186077739	Brilinta 90
00186077760	Brilinta 90
00186091542	Pulmicort Turbuhaler 200mcg 1x1EA Turbuhaler
00186091612	Pulmicort F
00186091706	Pulmicort F
00186107008	Rhinocort A
00186108805	Toprol-XL 2
00186108839	Toprol-XL 2
00186109005	Toprol-XL 5
00186109039	Toprol-XL 5
00186109050	Toprol-XL 50mg 30 count dose package
00186109205	Toprol-XL 1
00186109239	Toprol-XL 1
00186109405	Toprol-XL 2
00186190501	Foscavir 24mg/mL 250mL IV 12x250ML Package
00186190601	Foscavir 24mg/mL 500mL IV 12x500ML Package
00186198804	PULMICORT R
00186198904	PULMICORT R
00186199004	PULMICORT R
00186401001	Nexium For
00186402001	Nexium For
00186402501	Nexium For
00186404001	Nexium For
00186405001	Nexium For
00186423921	Aquasol A 50,000 USP Units/2mL 10x2ML Package
00186502031	Nexium 20mg
00186502054	Nexium 20mg
00186502082	Nexium 20mg
00186502228	Nexium 20mg
00186504031	Nexium 40mg
00186504035	Nexium 40mg
00186504054	Nexium 40mg
00186504055	Nexium 40mg
00186504082	Nexium 40mg
00186504085	Nexium 40mg
00186504225	Nexium 40mg
00186504228	Nexium 40mg
00186602001	Nexium IV f

00186604001	Nexium IV f
00186730005	Metoprolol Succinate 25mg 100x1 TAB BTL
00186730105	Metoprolol Succinate 50mg 100x1 TAB BTL
00186730205	Metoprolol Succinate 100mg 100x1 TAB BTL
00186730305	Metoprolol Succinate 200mg 100x1 TAB BTL
00310010110	Tenormin 10
00310010510	Tenormin 50
00310010710	Tenormin 25
00310010810	Tenormin I.V. Inj 6x10mL 5 mg/10 mL AMP
00310011510	Tenoretic 5
00310011710	Tenoretic 1
00310013010	Zestril 5mg 1x100TAB Bottle
00310013011	Zestril 5 m
00310013039	Zestril 5mg 1x100TAB Hospital Unit Dose
00310013110	Zestril 10m
00310013111	Zestril 10m
00310013210	Zestril 20m
00310013211	Zestril 20m
00310013310	Zestril 30mg 1x100TAB Bottle
00310013311	Zestril 30m
00310013410	Zestril 40m
00310013510	Zestril 2.5
00310014110	Zestoretic 10/12.5mg 1x100TAB Bottle
00310013411	Zestril 40
00310013510	Zestril 2.5
00310013511	Zestril 2.5
00310014111	Zestoretic
00310014210	Zestoretic
00310014211	Zestoretic
00310014510	Zestoretic
00310014511	Zestoretic
00310020130	Arimidex 1m
00310020150	Arimidex 1mg 30 count dose package
00310020860	Zomig Nasal
00310020920	Zomig-ZMT 2
00310021020	Zomig 2.5mg
00310021125	Zomig 5mg 1
00310021321	Zomig-ZMT 5
00310027110	Seroquel 10
00310027139	Seroquel 10
00310027210	Seroquel 20
00310027239	Seroquel 20
00310027439	Seroquel 30
00310027460	Seroquel 30

00310027510	Seroquel 25
00310027534	Seroquel 25
00310027539	Seroquel 25
00310027810	Seroquel 50
00310027834	Seroquel 50
00310027839	Seroquel 50
00310027910	Seroquel 40
00310027939	Seroquel 40
00310028039	Seroquel XR
00310028060	Seroquel XR
00310028139	Seroquel XR
00310028160	Seroquel XR
00310028239	Seroquel XR
00310028255	Seroquel XR 200mg 1x500 Tablet Bottle
00310028260	Seroquel XR
00310028339	Seroquel XR
00310028355	Seroquel XR 300mg 1x500 Tablet Bottle
00310028360	Seroquel XR
00310028439	Seroquel XR
00310028455	Seroquel XR 400mg 1x500 Tablet Bottle
00310028460	Seroquel XR
00310032130	Merrem I.V.
00310032165	NOVAPLUS Me
00310032520	Merrem I.V.
00310032564	NOVAPLUS Me
00310037610	Cefotan Inj 1g/10mL 10x1EA VIAL
00310037720	Cefotan Inj 2g/20mL 10x1EA VIAL
00310037851	Cefotan Inj 1g/50mL 1x1EA (Galaxy Bag)
00310037951	Cefotan Inj 2g/50mL 1x1EA (Galaxy Bag)
00310040160	ACCOLATE 10
00310040239	ACCOLATE 20mg
00310040260	ACCOLATE 20
00310048230	Iressa 250m
00310060060	Nolvadex 10mg 1x60TAB Bottle
00310060430	Nolvadex 20mg 1x30TAB Bottle
00310070510	Casodex 50m
00310070530	Casodex 50m
00310070539	Casodex 50m
00310072010	Faslodex 50
00310072025	Faslodex 250mg/5ml 2 X 2 5 ML Pre-filled Syringe
00310072050	Faslodex 25
00310075139	Crestor 10m
00310075190	Crestor 10m
00310075239	Crestor 20m

00310075290	Crestor 20m
00310075430	Crestor 40m
00310075590	Crestor 5mg
00310095036	Zoladex Saf
00310095130	Zoladex Saf
00310108730	Dutoprol 25
00310109530	Dutoprol 50
00310109730	Dutoprol 10
00310782030	Caprelsa 10
00310783030	Vandetanib
00310784030	Caprelsa 30